Eurofins announces the cancellation of 10.8m repurchased shares


9 April 2025

Eurofins Scientific SE (the “Company” or “Eurofins”) (EUFI.PA) announces that its Board of Directors has
decided on the cancellation of 10,818,183 shares, representing 5.61% of the Company’s share capital, that
were repurchased as part of its share buyback programmes, which began in October 2022.

The cancellation of shares is in line with, among other objectives, the Company’s intention to reduce the
share capital as authorised by shareholders at the Annual General Meeting held on 25 April 2024.

Following this cancellation of repurchased shares, which is effective as of 08 April 2025, the total number of
Eurofins shares outstanding is now 182,163,000.



Notes to Editors:

For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food,
environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences
and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a
rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies
in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing
services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our
objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible
turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety
standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners
around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio
and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of
biotechnology and analytical chemistry to offer their clients unique analytical solutions.



Eurofins Scientific 1/2 April 2025
Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA,
Bloomberg ERF FP).




Eurofins Scientific 2/2 April 2025